LSTA
Lisata Therapeutics, Inc.·Healthcare
3.29
2.813%(+0.09)
Market OpenLast Updated: — ET
52W L: $1.8152W H: $5.07
LSTA NEWS
globenewswire.com
May 4
Halper Sadeh LLC is Investigating Whether SILA and LSTA are Obtaining Fair Deals for their Shareholders
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.
globenewswire.com
May 4
URGENT: The M&A Class Action Firm Launches Legal Inquiry for the Merger—LSTA, IBCP, HCBN, and SILA
NEW YORK, May 04, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde and Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report.
businesswire.com
Mar 26
Leading Financial Trade Associations, Led by LSTA, Submit Amicus Brief in Support of Defendant Lenders in Antitrust Case Filed by Optumum Communications
NEW YORK--(BUSINESS WIRE)--LSTA, the trade association for the U.S. corporate lending market, today was joined by SIFMA, the MFA, the Investment Company Institute and the Creditor Rights Coalition, in submitting an amicus brief in support of the defendant lenders in a misguided antitrust case filed by Optimum Communications, Inc. The complaint, one of the first of its kind, is an attempt to apply traditional antitrust principles to “Cooperation Agreements”, which have grown increasingly common.
proactiveinvestors.com
Mar 9
Lisata Therapeutics to be acquired by Kuva Labs
Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE), a clinical-stage pharmaceutical company developing therapies to treat advanced solid tumors and other serious diseases, announced that it has agreed to be acquired by privately held Kuva Labs. Under the terms of a definitive agreement, Kuva will launch a tender offer to purchase all outstanding Lisata shares for $5 per share in cash at closing, plus one contingent value right (CVR) per share.
prnewswire.com
Mar 9
Shareholder Alert: The Ademi Firm investigates whether Lisata Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders
MILWAUKEE, March 9, 2026 /PRNewswire/ -- Ademi LLP is investigating Lisata (NASDAQ: LSTA) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Kuva Labs Inc. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you.
proactiveinvestors.com
Mar 9
Lisata Therapeutics shares up 20% as Kuva Labs acquisition advances
Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE), a clinical-stage pharmaceutical company developing therapies to treat advanced solid tumors and other...
